PSA and acid phosphatase in the diagnosis of prostate cancer

Journal of Clinical Ligand Assay

Volumn 21, Issue 1, 1998, Pages 24-34

  Chu, T Ming ^a   Lin, Ming Fong ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Acid phosphatase; Diagnosis; Early detection; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

ACID PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CELL SPECIFICITY; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; POLYMERASE CHAIN REACTION; PROSTATE CANCER;

EID: 0031923726     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Chu TM, Wang MC, Lee CL, et al: Prostatic acid phosphatase in human prostate cancer, in Chu TM (ed): Biochemical Markers for Cancer. New York, Marcel Dekker, 1982, p 117.
2. Chu TM: Monoclonal antibodies to human prostate cancer related antigens, in Sell S, Reisfeld R(eds): Monoclonal Antibodies to Tumor Markers. Totowa, NJ, Humana Press, 1985, p 309.
3. Wang MC, Killian CS, Lee CL, et al: Monoclonal antibody for prostate cancer, in Kupchik H (ed): Cancer Diagnosis In Vitro Using Monoclonal Antibodies. New York, Marcel Dekker, 1987, p 195.
4. Killian CS, Chu TM: Prostate-specific antigen: Questions often asked. Cancer Invest 1990;8:27-37.
5. Chu TM: Prostate specific antigen (PSA) and early detection of prostate cancer. Tumor Biol 1997;18:123-134.
6. Wang MC, Valenzuela LA, Murphy GP, et al: Purification of a human prostate specific antigen. Invest Urol 1979;17:159-163.
7. Papsidero LD, Wang MC, Valenzuela LA, et al: A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980; 40:2428-2432.
8. Kuriyama M, Wang MC, Papsidero LD, et al: Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980; 40:4658-4662.
9. Kuriyama M, Wang MC, Lee CL, et al: Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 1981;41:3874-3876.
10. Papsidero LD, Kuriyama M, Wang MC, et al: Prostate specific antigen: A marker for human prostatic epithelial cells. J Natl Cancer Inst 1981;66:37-44.
11. Wang MC, Papsidero LD, Kuriyama M, et al: Prostate antigen: A new potential marker for prostate cancer. Prostate 1981;2:89-96.
12. Papsidero LD, Wang MC, Kuriyama M, et al: Human prostate epithelial cell-specific antigen, in Murphy GP (ed): The Prostatic Cell. Alan R. Liss, New York, 1981, p 435.
13. Wang MC, Kuriyama M, Papsidero LD, et al: Prostate antigen of human cancer patients, in Busch H, Yeoman LC (eds): Methods in Cancer Research. Vol 19, New York, Academic Press, 1982, pp 179-197.
14. Wang MC, Loor RM, Li SL, et al: Physico-chemical characterization of prostate specific antigen purified from human prostate gland and seminal plasma. Int Res Commun System Med Sci 1983;11:327-328.
15. Ban Y, Wang MC, Watt KW, et al: The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Comm 1984;123:482-488.
16. Watt K, Lee P, M'Timkulu T, et al: Human prostate-specific antigen: Structural and functional similarity with serine protease. Proc Natl Acad Sci 1985;83:3166-3170.
17. Wang MC, Valenzuela LA, Muphy GP, et al: a simplified purification procedure for human prostate antigen. Oncol 1982;39:1-5.
18. Papsidero, LD, Croghan, GA, Wang, MC, et al: Monoclonal antibody (F5) to human prostate specific antigen. Hybridoma 1983;2:139-147.
19. Cooner WH, Molsey BR, Rutherford CL, et al: Clinical application of transrectal ultrasonography and prostate-specific antigen in the search for prostate cancer. J Urol 1988;39:758-761.
20. Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate-specific-antigen. J Urol 1992;147:841-845.
21. Littrup PJ, Lee F, Mettlin CJ: Prostate cancer screening: Current trends in future implications. CA Cancer J Clin 1992;42:198-211.
22. Catalona WJ, Smith DD, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl J Med 1991;324:1156-1161.
23. Catalona WJ, Smith DD, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-954.
24. Epstein JI, Walsh PC, Carmichael M, et al: Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
25. Walsh PC: Prostate cancer kills: Strategy to reduce deaths. Urol 1994;44:463-466.
26. Ohiro M, Scardino PT: Early detection of prostate cancer. The nature of cancerdetected with current diagnostic tests. Semin Oncol 1994;21:522-526.
27. Ries L, Kosary C. Prostate cancer incidence, 1973-1994. J Natl Cancer Inst 1997;89:609.
28. Kramer BS, Brown ML, Prorok PC, et al: Prostate cancer screening: What we know and what we need to know. Ann Intern Med 1993;119:914-923.
29. Coley CM, Barry MJ, Fleming C, et al: Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Annu Intern Med 1997;126(5):394-406.
30. Gohagan JK, Prorok PC: The prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. Cancer 1995;75:1869-1873.
31. Wilt TJ, Barry MJ: The prostate cancer intervention versus observation trial (PIVOT). Urol Int 1995;3:16-17.
32. Benoit RM, Naslund MJ: The socioeconomic implications of prostate-specific antigen screening. Urol Clin North America 1997;242:451-458.
33. Mettlin CJ, Jones GW, Averette H, et al: Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancer. CA Cancer J Clin 1993;43:42-46.
34. von Eschenbach A, Ho R, Murphy GP, et al: American Cancer Society guideline for the early detection of prostate cancer: Update 1997. CA Cancer J Clin 1997;47:261-264.
35. Carter HB, Pearson JD: Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North America 1997;24:333-338.
36. Smith DS, Catalona WJ: Rate of change in serum prostate specific antigen level as a method for prostate cancer detection. J Urol 1994;152:1163-1167.
37. Carter HB, Epstein JI, Chan DW, et al: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277:1456-1460.
38. Thiel R, Pearson JD, Epstein, JI, et al: Role of prostate-specific antigen velocity in prediction of final pathological stage in men with localized prostate cancer. Urol 1997;49:716-720.
39. Partin AW, Kattan MM, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-1451.
40. Kattan MW, Stapleton AMF, Wheeler TM, et al: Evaluation of a nomogram used to predict the pathological stage of clinically localized prostate carcinoma. Cancer 1997;79:528-537.
41. D'Amico AV, Whittington R, Malkowicz SB, et al: Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis of an adjuvant therapy trial. J Clin Oncol 1997;15:1465-1469.
42. Benson MC, Whang IS, Pantuck A, et al: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-816.
43. Keetch DW, McMurtry JM, Smith DS, et al: Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol 1996;156:428-431.
44. Gohji K, Nomi M, Egawa S, et al: Detection of prostate carcinoma using prostate specific antigen, its density and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer 1997;79:1969-1976.
45. Henderson RJ, Eastham JA, Culkin DJ, et al: Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst 1997;89:134-138.
46. Brawer MK, Aramburu WA, Chen GL, et al: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinomas. J Urol 1993;150:369-373.
47. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-864.
48. Oesterling JE, Kumamoto Y, Tsukamoto T, et al: Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Brit J Urol 1995;75:347-353.
49. Richardson TD, Oesterling JE: Age-specific reference ranges for serum prostate specific antigen. Urol Clin North America 1997;24:339-351.
50. Moul JW, Sesterhenn IA, Connelly RR, et al: Prostate-specific antigen value at the time of prostate cancer diagnosis in African-American men. JAMA 1995;274:1277-1281.
51. Morgan TO, Jacoben SJ, McCarthy WF, et al: Age-specific reference ranges for serum prostate-specific antige in black men. New Engl J Med 1996;355:304-310.
52. Speights VO, Brawn PN, Foster DM, et al: Evaluation of age-specific normal ranges for prostate-specific antigen. Urol 1995;45:454-457.
53. El-Galley RE, Petros JA, Sanders WH, et al: Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urol 1995;46:200-204.
54. Partin AW, Criley SR, Subong EN, et al: Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer. A pathological analysis. J Urol 1996;155:1336-1339.
55. Chu TM, Kuriyama M, Johnson E, et al: Circulating antibody to prostate antigen in patients with prostate cancer. Transplant Proc. 1984;16:481-485.
56. Stenman UH, Leinonen J, Alfthan H, et al: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
57. Christensson A, Bjork T, Nilsson O, et al: Serum prostate-specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-105.
58. Chu TM, Kawinski E, Hibi N, et al: Prostate-specific antigenic domain of human prostate-specific antigen identified with monoclonal antibodies. J Urol 1989;141:152-156.
59. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-1220.
60. Vashi AR, Wojno KJ, Henricks W, et al: Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urol 1997;49:19-27.
61. Carter HB, Partin AW, Luderer AA, et al: Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urol 1997;49:379-384.
62. McLaren DB, McKenzie M, Duncan G, et al: Watchful waiting or watchful progression? Prostate specific antigen doubling time and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998;82:342-348.
63. Van Cangh PJ, De Nayer P, Sauvage P, et al: Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate-Supplement 1996;7:30-34.
64. Woodrum DL, Brawer MK, Partin AW, et al: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.
65. Moore RA: Free PSA as a percentage of the total: where do we go from here? Clin Chem 1997;43:1561-1562.
66. Nadji M, Tabei SZ, Castro A, et al: Prostatic specific antigen: An immunohistologic marker for prostatic neoplasms. Cancer 1981;48:1229-1232.
67. Deguchi T, Doi T, Ehara H, et al: Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993;53:5350-5354.
68. Deguchi T, Yang M, Kawada Y: Micrometastasis of prostate cancer to lymph nodes: Detection by means of reverse transcription-poly merase chain reaction. J Natl Cancer Inst 1997;89:1471-1473.
69. Diamandis EP, Yu H: Prostate cancer, prostate-specific antigen, and the polymerase chain reaction. Clin Chem 1995;41:177-179.
70. Hamdy FC, Lawry J, Anderson JB, et al: Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br J Urol 1992;69:392-396.
71. Moreno JG, Croce CM, Fischer R, et al: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992;52:6110-6112.
72. Katz AE, deVries GM, Begg MD, et al: Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995;75:1642-I648.
73. Corey E, Arfman EW, Liu AY, et al: Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. Clin Chem 1997;43:443-452.
74. Smith MR, Biggar S, Hussain M: Prostate-specific antigen messenger RNA is expressed in non-prostate cells: Implications for detection of micrometastases. Cancer Res 1995;55:2640-2644.
75. Diamandis EP, Yu H: Nonprostatic sources of prostate-specific antigen. Urol Clin North America 1997;24:275-282.
76. Junker R, Brandt B, Semjonow A, et al: Measurement of prostate-specific antigen: No advantage to ultrasensitive assays? J Natl Cancer Inst 1996;88:1594-1595.
77. Diamandis EP: Clinical application of ultrasensitive prostate-specific antigen assays. J Natl Cancer Inst 1997;89:1077-1078.
78. Thiounn N, Saporta F, Flam TA, et al: Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urol 1997;50:245-250.
79. Baffa R, Moreno JG, Monne M, et al: A comparative analysis of prostate-specific antigen gene sequence in benign and malignant prostate tissue. Urol 1996;47:795-800.
80. Gomella LG, Raj GV, Moreno JG: Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 1997;158:326-337.
81. Kuriyama M, Wang MC, Lee CL, et al: Multiple marker evaluation in prostate cancer using tissue specific antigens. J Natl Cancer Inst 1982;68:99-105.
82. Huang CL, Brassil D, Rozzell M, et al: Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate 1993;23:201-212.
83. Anderson BR, Knorr UB, Brasso K, et al: Prostate-specific antigen, acid phosphatase and rectal exploration in the diagnosis of prostatic cancer. Ugeskrift for Laeger 1997;159:2538-2542.
84. Shimizu TS, Uchida T, Satoh, J, et al: Prostate-specific antigen in mass screening for carcinoma of the prostate. Int J Urol 1995;2:257-260.
85. Oesterling JE: Prostate specific antigen. Cancer 1995;75:1795-1804.
86. Lin MF, Lee, CL, Li SSL, et al: Purification and characterization of a new human prostatic acid phosphatase isoenzyme. Biochem 1983;22:1055-1062.
87. Gutman EB, Sproul EE, Gutman AB: Significance of increased phosphatase activity of bones at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936;28:485-495.
88. Lin MF, Clinton GM: Human prostatic acid phosphatase and its phosphotyrosyl-protein phosphatase activity. Advanced Protein Phosphatases 1987;4:199-228.
89. Chu TM, Wang MC, Merrin C, et al: Isoenzyme of human prostatic acid phosphatase. Oncol 1978;35:198-200.
90. Loor RM, Wang MC, Valenzuela LA, et al: Expression of prostatic acid phosphatase in human prostate cancer. Cancer Letters 1981;14: 63-69.
91. Solin T, Kontturi M, Pohlmann R, et al: Gene expression and prostate specificity of human prostatic acid phosphatase (PAcP): Evaluation by RNA blot analyses. Biochim Biophys Acta 1990;1048:72-77.
92. Li HC, Chemoff J, Chen LB, et al: A phosphoryl-protein phosphatase activity associated with acid phosphatase for human prostate gland. European J Biochem 1984;138:5-51.
93. Lin MF, Clinton GM: Prostatic acid phosphatase has phosphotryosy phosphatase activity. Biochem J 1986;235:351-357.
94. Nguyen L, Chapdelaine A, Chevalier S: Prostatic acid phosphatase in serum of patients with prostatic cancer is a specific protein J tyrosine phosphatase. Clin Chem 1990;36:1450-1455.
95. Lin MF, Lee CL, Clinton GM: Tyrosyl kinase activity is inversely related to PAcP activity in two human prostatic carcinoma cell lines. Mol Cell Biol 1986;6:4753-4757.
96. Lin MF, Clinton GM: The epidermal growth factor receptor from prostate cells is dephosphorylated by a prostate-specific phosphotyrosyl phosphatase. Mol Cell Biol 1988;8:5477-5485.
97. Lin MF, DaVolio J, Garcia-Arenas R: Expression of human prostatic acid phosphatase activity and the growth of prostate carcinomacell. Cancer Res 1992;52:4600-4607.
98. Vihko P, Virkkunen P, Henttu P, et al: Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Letters 1988;236:275-281.
99. Sharief FS, Lee H, Leuderman MM, et al: Human prostatic acid phosphatase: cDNA cloning, gene mapping and protein sequence homology with lyososmal acid phosphatase. Biochem Biophys Res Commun 1989;160:79-86.
100. Lin MF, Garcia-Arenas R, Xia XZ, et al: The cellular level of prostatic acid phosphatase and the growth of human prostate carcinoma cells. Differentiation 1994;57:143-149.
101. Lin MF, Meng TC, Rao PS, et al: Expression of human prostatic acid phosphatase correlates with androgen stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998;273:5939-5947.
102. Fong L, Ruegg CL, Brockstedt D, et al: Induction of tissue-specific auto-immune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997;159:3113-3117.
103. Liu KJ, Chatta GS, Twardzik DR, et al: Identification of rat prostatic steroid binding protein as target antigen of experimental autoimmune prostatatis: Implications for prostate cancer therapy. J Immunol 1997;159:472-480.